AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00332202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
Study NCT00332202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, daily
Study NCT03011645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Given by mouth, single dose of 60 mg.
Study NCT03011645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: Given by mouth, single dose of 20 mg.
Study NCT03011645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Given by mouth, single dose.
Study NCT02471690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oritavancin
Description: IV - Single dose 1200 mg Oritavancin
Study NCT02129426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Sedation medication
Study NCT02129426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Sedation medication
Study NCT02129426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Sedation medication
Study NCT02471690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: D5W 5% in Water
Study NCT03481270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concordant
Description: We will be randomizing across providers - we are particularly interested in racial concordance.
Study NCT03481270 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Concordant
Description: We will be randomizing across providers - we are particularly interested in racial concordance.
Study NCT03880877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
Study NCT03880877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
Study NCT03880877 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA6/TA6)
Description: The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
Study NCT03880877 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA6/TA7)
Description: The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
Study NCT03880877 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA7/TA7)
Description: The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
Study NCT03880877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin and 5-FU
Description: Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
Study NCT02129426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Sedation medication
Study NCT04438707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Method combined with Therapeutic exercice.
Description: Children must perform specific exercices in this combined method with the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
Study NCT04438707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: Children must perform specific exercices without the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
Study NCT01619930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity without motivational interviewing
Description: Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback.
Study NCT01619930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise with motivational interviewing
Description: Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback. An initial motivational interview (MI) per telephone is also conducted, to explore the intrinsic motivation to change in participants.
Study NCT01619930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation with rationale
Description: A behavioral activation program, based on the TRAP-TRAC model according to which suffering individuals are trapped in a vicious circle of avoidance and ever fewer reinforcers, leading to increasing discomfort. To break free of this vicious circle, patients have to replace avoidance patterns with alternative coping strategies. Unlike previous applications of this program done in the U.S., this study will feature an internet-based administration. Approximately 15 minutes of electronic therapist support will be included per week.
Study NCT02825290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate
Study NCT04308733 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days
Study NCT04308733 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Anodal tDCS
Description: patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days
Study NCT04348227 — intervention group
Intervention type: BEHAVIORAL
Intervention: Enhanced hygiene measures
Description: Wether or not hygiene measures dictated by the pandemic of severe acute respiratory syndrome coronavirus 19 , reduce multi drug resistant pathogens isolated in endotracheal aspirates.
Study NCT01129583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
Study NCT01129583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
Study NCT02898285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team sports
Description: Participants will choose from a list of team sports and will be signed up with the team.
Study NCT02898285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual sport condition
Description: Participants will choose from a list of individual sports.
Study NCT02898285 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Night out
Description: Participants in this group will be asked to go out to have a weekly night out or personal time of choice, such as dinner or a movie (only restrictions are they cannot go do a sport or physical activity and time must be spent without children).
Study NCT03515291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iMP cells
Description: Immunomodulatory progenitor cells
Study NCT03515291 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control injection
Description: Cell suspension solution
Study NCT03787381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: Vaginal ultrasound examination
Study NCT03873675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: parathyroid hormone
Description: 10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
Study NCT00866008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation
Description: 1. Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~2. Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
Study NCT02876250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
Study NCT02876250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
Study NCT03501927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS (focused cardiac ultrasound)
Description: A ultrasound of the heart and pleura will be performed. This provide information on~* Left ventricular systolic function~* Left ventricular diastolic function~* Right ventricular systolic function~* Right ventricular pressure overload~* Biventricular sizes~* Pathology of the mitral- and aortic valves~* Pericardial fluid~* Gross fluid status~* Pleural effusion
Study NCT02926807 — intervention group
Intervention type: OTHER
Intervention: FDG-PET Scan
Description: a 18FDG-PET to quantify vascular inflammation
Study NCT02926807 — intervention group
Intervention type: OTHER
Intervention: MDCT
Description: a MDCT to calculate the Agatston score
Study NCT02926807 — intervention group
Intervention type: OTHER
Intervention: biopsy and blood collection
Description: biopsy and blood collection to assess biomarkers
Study NCT04815837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 1. Viewing a video promoting Human Papillomavirus (HPV) vaccination: participants will watch a 5-minute online video promoting MSM's uptake of HPV vaccination. In the video, a peer MSM discussed about the risk of contracting HPV and having anal cancers among MSM, severe consequences of HPV-related diseases, as well as the benefits of HPV vaccination. He also demonstrated the procedures of taking up HPV vaccination in the collaborative private clinics, which portrayed caring, privacy guaranteed, and non-judgmental environment.~2. Receiving the discount coupons: each participant will be given a discount coupon. By using the coupon, one can enjoy a 10% discount for taking up three doses of HPV vaccines at a collaborating private clinic.~3. Visiting the project webpage: Participants can assess the project webpage by scanning the QR code on the discount coupon.~4. Follow-up reminders: participants received five reminders at Month 1, 2, 4, 6, \& 8.
Study NCT01216774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM
Study NCT01216774 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strength training
Description: Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM
Study NCT01216774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM
Study NCT03551522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar
Description: 10 mg, 20 mg, or 50 mg
Study NCT03551522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Matching placebo Capsule
Study NCT03388814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration of bupivacaine
Description: Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine. These injections will occur at the end of the mastectomy and prior to the insertion of the tissue expander implant. The local anesthetic will be injected into the chest wall and skin flaps. Attending physicians and resident physicians will receive prior instruction regarding correct placement of the local anesthetic so that it will be consistently placed in the same locations with similar volume distribution.
Study NCT03388814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pectoralis Nerve block
Description: Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane between the serratus anterior and the pectoralis minor muscles at approximately the level of the 4th rib and 10 ml of the same solution in the tissue plane between the two pectoralis muscles at approximately the 3rd rib under ultrasound guidance on the surgical side preoperatively.
Study NCT02503605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biosimilar recombinant FSH
Description: Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
Study NCT02503605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urinary FSH
Description: Controlled ovarian stimulation with 150 IU/day urinary FSH
Study NCT04312087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral neck sentinel lymph node biopsy
Description: Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.
Study NCT04312087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified lateral neck lymph node dissection
Description: Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).
Study NCT04312087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Super selective lateral neck lymph node dissection
Description: Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).
Study NCT05284695 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Patients undergoing elective bariatric surgery
Study NCT03637049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050 and midazolam
Description: A single oral dose of midazolam (1 mL of 2mg/mL syrup) will be given to all subjects in Period 1 and on Day 5 of Period 2. 1200 mg of PBI-4050 (3 X 400 mg tablets) will be administered for 5 days (Day 1 to Day 5) of Period 2 and a single dose of midazolam (1 mL of 2mg/mL) on Day 5.
Study NCT01392183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg by mouth daily in 4 week study cycle.
Study NCT01392183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
Study NCT01392183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
Study NCT01392183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benadryl
Description: 25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
Study NCT00757315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NdYag Laser(hair removal laser) plus topical corticosteroid
Description: NdYag laser and topical corticosteroid are applied to one half of the scalp.
Study NCT00757315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroid alone
Description: topical corticosteroid alone is applied to one half of the scalp
Study NCT03791632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classical lecture style presentation
Description: classical lecture style presentation
Study NCT03791632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: an intervention in the form of fun workshops
Description: an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
Study NCT03791632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital media intervention
Description: digital media intervention
Study NCT02157454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website access
Description: Access to the colorectal cancer module of the website www.krankheitserfahrungen.de which provides free, reliable information about health issues by sharing people's real-life experiences
Study NCT01920906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy and blood test
Description: Analysis of histology and gene expression in affected and unaffected skin
Study NCT00492843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate (Bondronat)
Description: Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
Study NCT00492843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate (Bondronat)
Description: Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
Study NCT01738022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of gas mixtures
Study NCT04533711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OA-PCP Intervention
Description: The OA-PCP intervention includes brief physical activity (PA) counseling delivered via phone by a PA Coach trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA Coach will ask participants about their current physical activity level and work with them to set physical activity goals. Then, after the first call, participants in this group will receive a call about two weeks later, then at about 3 months, 6 months, 9 months and 12 months later. During these calls, the PA coach will ask participants' about their progress toward PA goals and work with them to address any barriers or challenges. The coach will also help participants to identify any programs or resources that may help them to achieve their PA goals. Participants in this group will be asked to wear a wrist-worn monitor to help them track their PA during the intervention period. Also, if participants approve, the coach will use an online program to view their PA data.
Study NCT04533711 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: This group will receive an intervention in the same dose (e.g., number and duration of phone calls and emails) as the OA-PCP group, but the content will not be PA-specific. During the first call, the Coach will discuss 2 topics, for which the amount of content parallels call #1 for the OA-PCP: What is OA? OA Diagnosis and OA Risk Factors. During the second call, the Coach will discuss the topic of Health Care Providers and Overview of OA Treatment Guidelines. Call topics for 3, 6, 9 and 12- month follow-up calls will be: Pain Medications, Mechanical Treatments (e.g., knee braces, footwear, joint protection), Complimentary and Alternative Therapies and discussion of OA and Mental Health, Sleep and Fatigue.
Study NCT00408863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tibolone
Description: tibolone 2.5 mg/day
Study NCT01619930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation without rationale
Description: A behavioral activation program without TRAP-TRAC rationale, but with some encouragement provided (Activate yourself and feel better!). Approximately 15 minutes of electronic therapist support will be included per week.
Study NCT02874664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab Tesirine
Description: Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
Study NCT00408863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03099733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text message
Description: Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
Study NCT04850183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on disease management on the quality of life, and anxiety and depression about Rheumatoid Arthritis
Description: The patients in the intervention group participated in a one-to-one training program consisting of a 30-min onset session.
Study NCT01475734 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide
Description: subcutaneous injection
Study NCT01475734 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection
Study NCT03077373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling letter
Description: The brief counseling letter intervention aiming to reduce physical inactivity, sedentary time in leisure time as well as smoking is based on behavior change theories (Transtheoretical model of health behavior change and Health Action Process Approach).~The computerized intervention system includes up to six interactions with participants. Recurrent assessments are initiated by the system and provide data for scheduling the proceeding intervention steps and selection of relevant content. Physical activity, sedentary time, smoking, and motivational measures to change or maintain behaviors according to the recommendations will be monitored over time and used to provide feedback in the form of letters.